drugset / Trial / NCT07065968
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Phase 2
Recruiting
132 enrolled
Peking University People's Hospital
Cisen Pharmaceutical CO., LTD. · collabPeking University Health Science Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2025-08-19
- Primary completion
- 2027-09-10
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Teriflunomide | Small molecule | 14 mg | Oral |